GPC3

GPC3

A gene on chromosome Xq26.1 that encodes glypican 3, a cell surface proteoglycan with heparan sulfate that inhibits the dipeptidyl peptidase activity of DPP4. It may be involved in modulating growth of mesodermal tissues, in IGF2-receptor interactions, and in cellular growth and tumourigenesis.

Molecular Pathology
Defects in GPC3 cause Simpson-Golabi-Behmel syndrome.
References in periodicals archive ?
In in vivo and in vitro preclinical studies, GPC3-CAR-T effectively killed GPC3 positive HCC cells.
The study presented at the International Liver Congress 2014 detected and expanded MHC-multimer-positive CD8+ T-cells specific for targeted GPC3 epitopes and grew T-cell clones, from which the most specific and active T-cell receptor was isolated.
The researchers found that that when this T-cell receptor was expressed on donor T cells it conferred specificity for GPC3, the HCC-associated antigen, enabling HLA-A2+ patient's T cells to specifically kill GPC3+ HCC.
This will allow the GPC3 (Human Glypican-3) ELISA Kit for detecting GPC3 in human serum or plasma, and the GPC3 (Human Glypican-3) Monoclonal Antibody (clone 1G12) to detect GPC3 in tissue by immunohistochemistry (IHC), to be marketed in the European Union.
The anti-GPC3 monoclonal antibody (MAb; clone 1G12) has also been used to assess GPC3 expression in malignant and non-malignant liver tissue samples and for ELISA detection of GPC3 in the serum.
The products include the monoclonal antibody pre-diluted for immunohistochemistry (IHC) and an enzyme-linked immunosorbant assay (ELISA) for detection of GPC3 in serum.
By implementing an early diagnostic test such as the detection of GPC3, it may be possible to improve clinical outcomes through screening and therapeutic monitoring.
Many studies have shown that, using the 1G12 antibody, GPC3 is detected at the protein level by immunohistochemistry in most cases of primary liver cancer, including small tumors.
When applying 2 markers, the combination of HSP70 and GPC3 seems to be best with 59% sensitivity and 100% specificity for well-differentiated HCC in resected cases.
Cell line/origin Selection Proteins References agent involved in the drug-resistant phenotype Gastric carcinoma EPG85-257P - - Lage (2003) EPG85-257RNOV Mitoxantrone BCRP, GPC3, Lage (2003) Topo II (1), TAP (1) EPG85-257RDB Daunorubicin MDR1/P-gp Lage (2003) Pancreatic carcinoma EPP85-181P - - Lage and Dietel (2002) EPP85-181RNOV Mitoxantrone Topo II Lage and Dietel (2002) EPP85-181RDB Daunorubicin MDR1/P-gp Lage and Dietel (2002) Colon carcinoma HT-29 - - Liu et al.
Simpson-Golabi-Behmel syndrome is an X-linked condition characterised by pre- and postnatal overgrowth with visceral and skeletal anomalies due to a defect in the GPC3 gene, which plays a role in control of growth of embryonic mesodermal tissues (1).
GPC3 is overexpressed in the majority of liver cancers (hepatocellular carcinoma (HCC), and in preclinical studies, KJgpc3-001 eradicated HCC cells.